Intended for the treatment of agitation associated with Alzheimer's disease. According to the CDE official website, Hansoh’s Class 1 new drug HS-10380 tablets has obtained implicit approval for clinical trials and is intended to be used to treat agitation related to Alzheimer’s disease.

Forecasts on the development trend of Alzheimer's disease and other forms of dementia in China show that the number of AD patients in China among people aged 60 and above will reach 19.11 million, 24.71 million and 27.65 million respectively in 2030, 2040 and 2050. . Under the influence of various factors such as the accelerated aging of my country's population and the increasing prevalence of major cardiovascular diseases and related factors, the prevalence and number of patients with Alzheimer's disease are also increasing year by year.

HS-10380 tablets are a multi-target agonist of D2, D3 receptors and 5-HT1A partial receptors developed by Hansoh Pharmaceuticals, a subsidiary of Hansoh Pharmaceuticals. It has a significant antagonistic effect on 5-HT2A receptors and is expected to improve Symptoms of people with mental illness. Currently, Hansoh Pharma is conducting multiple clinical studies of HS-10380 tablets for patients with schizophrenia. In July 2024, the clinical trial application for HS-10380 tablets for manic episodes in bipolar I disorder was also approved by the CDE. This time, HS-10380 tablets have been approved for clinical trials for Alzheimer’s disease.

According to public information, Hansoh Pharmaceutical has also deployed a number of new drugs in the field of the nervous system, including the product under development in the depression track, HS-10353. This drug is a positive modulator of GABA receptors and has 2 Phase 1 clinical trials are ongoing.

https://news.yaozh.com/